About deferasirox
Iron-chelating agent
Used for
- Treats chronic iron overload from repeated blood transfusions.
- Treats chronic iron overload in some people with non-transfusion-dependent thalassemia.
Usual adult dose
Transfusional overload: usually 20 mg/kg once daily. Non-transfusion-dependent thalassemia: usually 10 mg/kg once daily.
Usual dose in children
Used in children aged 2 years and older for transfusional iron overload; usual starting dose is 20 mg/kg once daily.
Common side effects
- Nausea, vomiting, diarrhea, or abdominal pain
- Rash
- Increased liver enzymes
- Increased blood creatinine
Important warnings
- Can cause kidney failure, liver failure, or gastrointestinal bleeding.
- Blood counts, kidney function, liver function, and iron levels require monitoring.
- Avoid with severe kidney or liver disease, or low platelet counts.
- Seek urgent care for severe abdominal pain, vomiting blood, or black stools.
Pregnancy
Human pregnancy information is limited; potential fetal harm is possible. Use only when clearly needed.
Breastfeeding
It is unknown whether deferasirox passes into human milk; breastfeeding decisions require professional guidance.
Interactions
- Antacids containing aluminum can reduce iron-chelation effects.
- May increase bleeding risk with anticoagulants or other ulcer-causing medicines.
- Rifampin, phenytoin, and other enzyme-inducing medicines may reduce deferasirox levels.
- Deferasirox can increase levels of medicines such as repaglinide and theophylline.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.